K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · MRK
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | MRK | MERCK & CO INC | MERCK & CO, INC. | $4.2M | S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues |
| 2026-04-20 | MRK | MERCK & CO. INC. | THE NICKLES GROUP, LLC | $70K | Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes. Issues related to tariffs. |
| 2026-04-20 | MRK | MERCK & CO INC | WILLIAMS AND JENSEN, PLLC | $50K | Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues. Tax policy impacting health care and pharmaceutical industry; implementation of PL 119-21. Drug pricing proposals. Pharmacy Benefit Manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation and ORPHAN CURES Act, Implementation of IRA, and policy changes including the EPIC Act, Medicaid drug rebate program, Issues related to drug pricing in Medicare Parts B and D; Issues related to Most Favored Nation (MFN) drug pricing proposals. General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Pharmacy Benefit Manager (PBM) policy issues. Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP. |
| 2026-04-20 | MRK | MERCK | TARPLIN, DOWNS & YOUNG, LLC | $50K | Federal budget issues IRA, innovation, drug pricing in federal programs, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars, PAHPA IRA, Medicare and Medicaid payment and coverage issues |
| 2026-04-20 | MRK | MERCK & CO. INC. | TODD STRATEGY GROUP | $50K | 340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues. Drug Pricing. S.864: HELP Copays Act. |
| 2026-04-20 | MRK | MERCK & CO. INC. | AVENUE SOLUTIONS | $50K | Issues related to vaccines; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC) Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to the implementation of the Inflation Reduction Act of 2022; Issues related to Senate Finance Dear Colleague process |
| 2026-04-20 | MRK | MERCK & CO. INC. | CROSSROADS STRATEGIES, LLC | $40K | Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) imp |
| 2026-04-19 | MRK | MERCK KGAA DARMSTADT GERMANY | FORBES-TATE | $80K | Issues related to chemical manufacturing. Issues related to domestic and international trade and tariff policies. Issues related to life sciences, laboratory and chemical manufacturing. |
| 2026-04-19 | MRK | TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) | TIBER CREEK HEALTH STRATEGIES, INC. | $50K | |
| 2026-04-18 | MRK | MERCK & CO. INC. | W STRATEGIES, LLC | $50K | Education around access to vaccines. Public Law 119-21: One Big Beautiful Bill Act. |
| 2026-04-18 | MRK | MERCK & CO. INC | TIBER CREEK GROUP | $50K | Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act. Issues related to intellectual property protections. Issues related to vaccine policy. |
| 2026-04-18 | MRK | MERCK ANIMAL HEALTH | FORBES-TATE | $50K | Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. |
| 2026-04-16 | MRK | MERCK SHARP & DOHME LLC | BALLARD PARTNERS | $80K | |
| 2026-04-09 | MRK | TIBER CREEK GROUP ON BEHALF OF MERCK & CO. INC. | B HALL STRATEGIES, LLC | $30K | Monitor issues related to drug pricing. |
| 2026-01-20 | MRK | MERCK & CO INC | MERCK & CO, INC. | $1.9M | S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2026 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues |
| 2026-01-20 | MRK | TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) | TIBER CREEK HEALTH STRATEGIES, INC. | $50K | |
| 2026-01-20 | MRK | MERCK & CO. INC | TIBER CREEK GROUP | $50K | Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act. Issues related to intellectual property protections. Issues related to vaccine policy. |
| 2026-01-20 | MRK | MERCK & CO. INC. | AVENUE SOLUTIONS | $50K | Issues related to vaccines; Expiring healthcare extenders Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to the implementation of the Inflation Reduction Act of 2022 |
| 2026-01-20 | MRK | MERCK & CO INC | WILLIAMS AND JENSEN, PLLC | $50K | General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Pharmacy Benefit Manager (PBM) policy issues. Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP. Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues. Tax policy impacting health care and pharmaceutical industry; implementation of PL 119-21. Drug pricing proposals. Pharmacy Benefit Manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation and ORPHAN CURES Act, Implementation of IRA, and policy changes including the EPIC Act, Medicaid drug rebate program, Issues related to drug pricing in Medicare Parts B and D; Issues related to Most Favored Nation (MFN) drug pricing proposals. |
| 2026-01-20 | MRK | MERCK & CO. INC. | THE NICKLES GROUP, LLC | $50K | Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 946/S. 1862, ORPHAN Cures Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes. Issues related to tariffs. |
| 2026-01-20 | MRK | MERCK | TARPLIN, DOWNS & YOUNG, LLC | $50K | Federal budget issues IRA, innovation, drug pricing in federal programs, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars, PAHPA IRA, Medicare and Medicaid payment and coverage issues |
| 2026-01-20 | MRK | MERCK & CO. INC. | HARBINGER STRATEGIES, LLC | $50K | Issues related to international tax policy. |
| 2026-01-20 | MRK | MERCK & CO. INC. | W STRATEGIES, LLC | $50K | Education around access to vaccines. Public Law 119-21: One Big Beautiful Bill Act. |
| 2026-01-20 | MRK | MERCK & CO. INC. | TODD STRATEGY GROUP | $50K | 340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues. Drug Pricing. S.864 - HELP Copays Act. |
| 2026-01-20 | MRK | MERCK & CO. INC. | CROSSROADS STRATEGIES, LLC | $40K | Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act, S.2296/H.R.3838/P.L.119-60), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Issues related to tax |
| 2026-01-19 | MRK | TIBER CREEK GROUP ON BEHALF OF MERCK & CO. INC. | B HALL STRATEGIES, LLC | $30K | Monitor issues related to drug pricing. |
| 2026-01-18 | MRK | MERCK KGAA DARMSTADT GERMANY | FORBES-TATE | $80K | Issues related to chemical manufacturing. Issues related to domestic and international trade and tariff policies. Issues related to life sciences, laboratory and chemical manufacturing. |
| 2026-01-18 | MRK | MERCK ANIMAL HEALTH | FORBES-TATE | $50K | Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. |
| 2026-01-14 | MRK | MERCK SHARP & DOHME LLC | BALLARD PARTNERS | $80K | |
| 2026-01-13 | MRK | MERCK KGAA DARMSTADT GERMANY | FORBES-TATE | $0 | Issues related to chemical manufacturing. |
| 2025-10-20 | MRK | MERCK & CO INC | MERCK & CO, INC. | $5.0M | H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella ( |
| 2025-10-20 | MRK | MERCK & CO INC | MERCK & CO, INC. | $1.5M | H.R. 1, One Big Beautiful Bill, issues related to health care S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Hea |
| 2025-10-20 | MRK | MERCK & CO. INC. | W STRATEGIES, LLC | $50K | Public Law 119-21: One Big Beautiful Bill Act. H.R.1492: EPIC Act. Education around access to vaccines. |
| 2025-10-20 | MRK | MERCK | TARPLIN, DOWNS & YOUNG, LLC | $50K | Federal budget issues IRA, innovation, drug pricing in federal programs, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars, PAHPA IRA, Medicare and Medicaid payment and coverage issues |
| 2025-10-20 | MRK | MERCK & CO INC | WILLIAMS AND JENSEN, PLLC | $50K | Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues. Tax policy impacting health care and pharmaceutical industry. H.R. 1, "One Big Beautiful Bill Act". Drug pricing proposals. Pharmacy Benefit Manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation and ORPHAN CURES Act, Implementation of IRA, and policy changes including the EPIC Act, Medicaid drug rebate program, Issues related to drug pricing in Medicare Parts B and D; Issues related to Most Favored Nation (MFN) drug pricing proposals. General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Pharmacy Benefit Manager (PBM) policy issues. Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP. |
| 2025-10-20 | MRK | MERCK & CO. INC. | AVENUE SOLUTIONS | $50K | Issues related to vaccines; Expiring healthcare extenders Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal |
| 2025-10-20 | MRK | MERCK & CO. INC. | TODD STRATEGY GROUP | $50K | 340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues. Drug Pricing. S.864 - HELP Copays Act. |
| 2025-10-20 | MRK | MERCK & CO. INC. | HARBINGER STRATEGIES, LLC | $50K | Issues related to international tax policy. |
| 2025-10-20 | MRK | TIBER CREEK GROUP ON BEHALF OF MERCK & CO. INC. | B HALL STRATEGIES, LLC | $30K | Monitor issues related to drug pricing. |
| 2025-10-19 | MRK | MERCK KGAA DARMSTADT GERMANY | FORBES-TATE | $80K | Issues related to chemical manufacturing. Issues related to domestic and international trade and tariff policies. Issues related to life sciences, laboratory and chemical manufacturing. |
| 2025-10-19 | MRK | MERCK & CO. INC | TIBER CREEK GROUP | $50K | Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act. Issues related to intellectual property protections. Issues related to the Advisory Committee on Immunization Practices (ACIP). |
| 2025-10-19 | MRK | TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) | TIBER CREEK HEALTH STRATEGIES, INC. | $50K | |
| 2025-10-18 | MRK | MERCK ANIMAL HEALTH | FORBES-TATE | $50K | Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. |
| 2025-10-18 | MRK | MERCK & CO. INC. | CROSSROADS STRATEGIES, LLC | $40K | Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals. H.R.1, One Big Beautiful Bill Act (P.L.119-21), all bio-pharmaceutical related provisions. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act, S.2296/H.R.3838), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. General issues related to Medicare and Medicaid, |
| 2025-10-17 | MRK | MERCK SHARP & DOHME LLC | BALLARD PARTNERS | $80K | Guidance and advocacy related to drug pricing and tariffs. Guidance and advocacy related to drug pricing and tariffs. |
| 2025-10-16 | MRK | MERCK & CO. INC. | THE NICKLES GROUP, LLC | $50K | Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 946/S. 1862, ORPHAN Cures Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to drug pricing and pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes. Issues related to tariffs. |
| 2025-10-16 | MRK | MERCK SHARP & DOHME LLC | BALLARD PARTNERS | $50K | Guidance and advocacy related to drug pricing and tariffs. Guidance and advocacy related to drug pricing and tariffs. |
| 2025-09-02 | MRK | MERCK SHARP & DOHME LLC | BALLARD PARTNERS | $0 | Guidance and advocacy related to drug pricing and tariffs. Guidance and advocacy related to drug pricing and tariffs. |
| 2025-07-21 | MRK | MERCK & CO INC | MERCK & CO, INC. | $5.0M | H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella ( |
| 2025-07-21 | MRK | MERCK & CO INC | WILLIAMS AND JENSEN, PLLC | $50K | Drug pricing proposals. Pharmacy Benefit Manager reform proposals. 340B. Vaccine access issues. Tax policy impacting health care and pharmaceutical industry. OBBB. Drug pricing proposals. Pharmacy Benefit Manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. Implementation of IRA. |
| 2025-07-21 | MRK | MERCK | TARPLIN, DOWNS & YOUNG, LLC | $50K | Federal budget issues IRA, innovation, 340B, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars, PAHPA IRA, Medicare and Medicaid payment and coverage issues |
| 2025-07-21 | MRK | MERCK & CO. INC. | AVENUE SOLUTIONS | $50K | Health care issues in H.R.1, To provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law No: 119-21); Issues related to vaccines Value of prescription drugs; Issues related to Medicare Parts B and D; Issues related to Medicare and Medicaid coverage and reimbursement; H.R. 946/S. 1862, ORPHAN Cures Act; Issues related to cyclic peptides; Issues related to Average Sales Price (ASP) and Part B Medicare negotiation; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R.4299, Protecting Patient Access to Cancer and Complex Therapies Act |
| 2025-07-21 | MRK | MERCK & CO. INC. | HARBINGER STRATEGIES, LLC | $50K | Issues related to international tax policy. |
| 2025-07-21 | MRK | MERCK & CO. INC. | CROSSROADS STRATEGIES, LLC | $40K | General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Issues related to tax reform; R&D tax credit; international taxation; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act. Issues related to pharmaceutical IP, supply chain, and tariffs. H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act), antimicrobial resistance, VICP Program, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Infl |
| 2025-07-21 | MRK | TIBER CREEK GROUP ON BEHALF OF MERCK & CO. INC. | B HALL STRATEGIES, LLC | $30K | Issues related to drug pricing in the One Big Beautiful Bill Act (PL 119-21). |
| 2025-07-20 | MRK | MERCK & CO. INC. | TODD STRATEGY GROUP | $40K | 340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues. Drug Pricing. S.864 - HELP Copays Act. |
| 2025-07-19 | MRK | MERCK & CO. INC | TIBER CREEK GROUP | $50K | Issues related to Medicare Part D and Part B Pricing Reform. Issues related to intellectual property protections. |
| 2025-07-19 | MRK | TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) | TIBER CREEK HEALTH STRATEGIES, INC. | $50K | |
| 2025-07-18 | MRK | MERCK & CO. INC. | W STRATEGIES, LLC | $50K | H.R.1 - One Big Beautiful Bill Act. H.R.1492: EPIC Act. |
| 2025-07-18 | MRK | MERCK & CO. INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $0 | |
| 2025-07-17 | MRK | MERCK & CO. INC. | THE NICKLES GROUP, LLC | $50K | Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 946/S. 1862, ORPHAN Cures Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. H.R.1, One Big Beautiful Bill Act, as it relates to drug pricing and pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. H.R. 1, One Big Beautiful Bill Act, as it relates to corporate taxes. Issues related to tariffs. Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity. |
| 2025-07-16 | MRK | MERCK KGAA DARMSTADT GERMANY | FORBES-TATE | $80K | Issues related to chemical manufacturing. Issues related to domestic and international trade and tariff policies. Issues related to life sciences, laboratory and chemical manufacturing. |
| 2025-07-16 | MRK | MERCK ANIMAL HEALTH | FORBES-TATE | $50K | Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. |
| 2025-07-15 | MRK | TIBER CREEK GROUP ON BEHALF OF MERCK & CO. INC. | B HALL STRATEGIES, LLC | $0 | Issues related to drug pricing and reimbursement of prescription drugs; Issues related to Medicare Part D and Part B Pricing Reform. |
| 2025-04-21 | MRK | MERCK & CO INC | MERCK & CO, INC. | $2.6M | H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts, labeling issues, and E-La |
| 2025-04-21 | MRK | MERCK & CO INC | MERCK & CO, INC. | $1.8M | H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 3633, PREVENT HPV Cancers Act of 2023 H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lo |
| 2025-04-21 | MRK | MERCK & CO. INC | TIBER CREEK GROUP | $50K | Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform. Issues related to intellectual property protections. |
| 2025-04-21 | MRK | MERCK & CO INC | WILLIAMS AND JENSEN, PLLC | $50K | Drug pricing proposals. Pharmacy Benefit Manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158). Tax policy impacting health care and pharmaceutical industry Drug pricing proposals. Pharmacy Benefit Manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158). |
| 2025-04-21 | MRK | MERCK & CO. INC. | AVENUE SOLUTIONS | $50K | S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4); Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation Value of prescription drugs; Issues related to Medicare Parts B and D; Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation; Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 1672, Maintaining Investments in New Innovation Act; Biosimilars Access and Affordability Act; H.R. 2484, Seniors Access to Critical Medications Act; H.R. 946, ORPHAN Cures Act |
| 2025-04-21 | MRK | MERCK & CO. INC. | HARBINGER STRATEGIES, LLC | $50K | Issues related to international tax policy. |
| 2025-04-21 | MRK | MERCK & CO. INC. | TODD STRATEGY GROUP | $40K | 340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues. Drug Pricing. S.864 - HELP Copays Act. |
| 2025-04-21 | MRK | MERCK & CO. INC. | CROSSROADS STRATEGIES, LLC | $40K | Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act), antimicrobial resistance, VICP Program, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Issues related to tax reform. Inflation Reduction Act of 2022 (P.L.117-169) implementation; issues related to international taxation. Issues related to R&D tax credit. Issues related to pharmaceutical IP, supply chain, and tariffs. H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4) |
| 2025-04-20 | MRK | MERCK | TARPLIN, DOWNS & YOUNG, LLC | $50K | IRA, innovation, 340B, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars, PAHPA IRA, Medicare and Medicaid payment and coverage issues patent reform, product hopping legislation Federal budget issues |
| 2025-04-18 | MRK | MERCK & CO. INC. | W STRATEGIES, LLC | $50K | Implementation of H.R.5376 - Inflation Reduction Act of 2022. H.R.1492: EPIC Act. Education around the Vaccine Injury Compensation Program. PBM reform legislation including efforts to delink fees in Medicare Part D. |
| 2025-04-18 | MRK | MERCK & COMPANY INC. | CAPITOL COUNSEL LLC | $0 | |
| 2025-04-18 | MRK | MERCK & CO. INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $0 | |
| 2025-04-17 | MRK | TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) | TIBER CREEK HEALTH STRATEGIES, INC. | $50K | Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). |
| 2025-04-17 | MRK | MERCK & CO. INC. | THE NICKLES GROUP, LLC | $50K | Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity. Issues related to drug pricing and implementation of the Inflation Reduction Act. Issues related to the extension of the Tax Cut and Jobs Act provisions impacting corporations. Issues related to tariffs. |
| 2025-04-15 | MRK | MERCK ANIMAL HEALTH | FORBES-TATE | $50K | Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. Issues related to health products and technology for animals and aquaculture. |
| 2025-04-14 | MRK | MERCK KGAA DARMSTADT GERMANY | FORBES-TATE | $80K | Issues related to chemical manufacturing. |
| 2025-02-14 | MRK | MERCK & CO. INC. | THE NICKLES GROUP, LLC | $0 | Issues related to prescription drugs. Issues related to tax policy. Issues related to prescription drugs. Issues related to tax policy. Issues related to prescription drugs. Issues related to tax policy. Issues related to prescription drugs. Issues related to tax policy. |
| 2025-01-31 | MRK | MERCK & CO. INC. | HARBINGER STRATEGIES, LLC | $0 | Issues related to international tax policy. |
| 2025-01-22 | MRK | MERCK & CO INC | WILLIAMS AND JENSEN, PLLC | $50K | Drug pricing proposals. Pharmacy Benefit Manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158). Tax policy impacting health care and pharmaceutical industry. Drug pricing proposals. Pharmacy Benefit Manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158). |
| 2025-01-22 | MRK | MERCK KGAA DARMSTADT GERMANY | FORBES-TATE | $10K | Issues related to chemical manufacturing. |
| 2025-01-21 | MRK | MERCK & CO INC | MERCK & CO, INC. | $1.7M | H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 3633, PREVENT HPV Cancers Act of 2023 H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lo |
| 2025-01-21 | MRK | MERCK & CO. INC. | W STRATEGIES, LLC | $50K | Implementation of H.R.5376 - Inflation Reduction Act of 2022. H.R.10545 - American Relief Act, 2025 as it relates to PBM reform. Education around the Vaccine Injury Compensation Program. H.R.5378 - Lower Costs, More Transparency Act. PBM reform legislation including efforts to delink fees in Medicare Part D. |
| 2025-01-21 | MRK | MERCK & CO. INC | TIBER CREEK GROUP | $50K | Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform. Issues relating to Intellectual Property protections. S.2333 - Pandemic and All-Hazards Preparedness and Response Act (provisions related to the Vaccine Injury Compensation Program and Vaccine Provisions). |
| 2025-01-21 | MRK | MERCK & CO. INC. | AVENUE SOLUTIONS | $50K | Antibiotics/stewardship; S.1355/H.R.2940, PASTEUR Act of 2023; Issues related to the Vaccine Injury Compensation Program (VICP); Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization; Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation; Issues related to HPV vaccine and ACIP recommendations; Issues related to 340b; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; H.R. 10545, American Relief Act, 2025 Value of prescription drugs; Issues related to Medicare Parts B and D; Issues related to Medicare and Medicaid coverage and reimbursement |
| 2025-01-21 | MRK | MERCK & CO. INC. | CROSSROADS STRATEGIES, LLC | $40K | Issues related to appropriations and federal health programs; reimbursement issues; H.R.9027/S.4690, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025; H.R.9029/S.4942, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025; H.R.10445, Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025; H.R.10545, American Relief Act, 2025. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, antimicrobial resistance legislation, and VICP Program; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; H.R |
| 2025-01-20 | MRK | TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) | TIBER CREEK HEALTH STRATEGIES, INC. | $50K | Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). |
| 2025-01-20 | MRK | MERCK & COMPANY INC. | CAPITOL COUNSEL LLC | $30K | Medicare Coverage and Reimbursement issues, including issues related to the Medicare Part B and D Coverage. Issues related to drug pricing. Package Inserts/E-Labeling Issues (H.R. 1503 Prescription Information Modernization Act of 2023). Issues related to the Vaccine Injury Compensation Program. |
| 2025-01-20 | MRK | MERCK & CO. INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $0 |